Verona Pharma (VRNA) News Today $86.78 +2.14 (+2.53%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$87.94 +1.16 (+1.33%) As of 07:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRNA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Verona Pharma (NASDAQ:VRNA) Hits New 52-Week High - Here's What HappenedVerona Pharma (NASDAQ:VRNA) Hits New 52-Week High - What's Next?June 10 at 10:01 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Receives Consensus Rating of "Buy" from AnalystsVerona Pharma plc (NASDAQ:VRNA - Get Free Report) has been assigned a consensus rating of "Buy" from the nine brokerages that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the companyJune 10 at 1:27 AM | marketbeat.comGAMMA Investing LLC Has $7.41 Million Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)GAMMA Investing LLC increased its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 7,135.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 116,631 shares of the company's stock after purchasingJune 9 at 4:01 AM | marketbeat.comRFG Advisory LLC Invests $1.48 Million in Verona Pharma plc (NASDAQ:VRNA)RFG Advisory LLC purchased a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 23,238 shares of the company's stock, valued at approximatelyJune 5, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Purchases 5,766 Shares of Verona Pharma plc (NASDAQ:VRNA)Hennion & Walsh Asset Management Inc. boosted its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 3.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 199,473 shares of the company's stock afteJune 3, 2025 | marketbeat.comHamilton Lane Advisors LLC Takes $1.65 Million Position in Verona Pharma plc (NASDAQ:VRNA)Hamilton Lane Advisors LLC acquired a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 26,057 shares of the company's stock, valued atJune 3, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Verona Pharma (NASDAQ:VRNA) StockJune 3, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High Following Analyst UpgradeJune 3, 2025 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Hits New 1-Year High After Analyst UpgradeVerona Pharma (NASDAQ:VRNA) Hits New 1-Year High Following Analyst UpgradeJune 2, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $90.00 at HC WainwrightHC Wainwright raised their price objective on Verona Pharma from $85.00 to $90.00 and gave the stock a "buy" rating in a research report on Monday.June 2, 2025 | marketbeat.comTwo Sigma Advisers LP Buys New Shares in Verona Pharma plc (NASDAQ:VRNA)Two Sigma Advisers LP bought a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 19,000 shares of the company's stock, valued at approximately $882,000.June 2, 2025 | marketbeat.com7,800 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by Northern Trust CorpNorthern Trust Corp acquired a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 7,800 shares of the company's stock, valued at approximateJune 2, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Sold by Bank of America Corp DEBank of America Corp DE decreased its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 85.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,651 shares of the company's stock after seJune 1, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up - What's Next?June 1, 2025 | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 32,432 SharesVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CFO Mark W. Hahn sold 32,432 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $9.53, for a total value of $309,076.96. Following the sale, the chief financial officer now directly owns 13,046,560 shares of the company's stock, valued at approximately $124,333,716.80. This trade represents a 0.25% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.May 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $320,208.00 in StockVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 33,600 shares of the stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $9.53, for a total value of $320,208.00. Following the completion of the transaction, the chief executive officer now owns 13,956,568 shares in the company, valued at approximately $133,006,093.04. The trade was a 0.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.May 31, 2025 | marketbeat.comDavid Zaccardelli Sells 157,704 Shares of Verona Pharma plc (NASDAQ:VRNA) StockVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 157,704 shares of the stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $9.30, for a total transaction of $1,466,647.20. Following the sale, the chief executive officer now directly owns 13,798,864 shares in the company, valued at approximately $128,329,435.20. This represents a 1.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.May 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 162,704 SharesVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CFO Mark W. Hahn sold 162,704 shares of the company's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $9.30, for a total transaction of $1,513,147.20. Following the transaction, the chief financial officer now directly owns 12,883,856 shares of the company's stock, valued at $119,819,860.80. This represents a 1.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.May 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 204,864 SharesVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CFO Mark W. Hahn sold 204,864 shares of the company's stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $9.33, for a total transaction of $1,911,381.12. Following the completion of the transaction, the chief financial officer now directly owns 12,678,992 shares in the company, valued at approximately $118,294,995.36. The trade was a 1.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.May 31, 2025 | marketbeat.comDavid Zaccardelli Sells 208,696 Shares of Verona Pharma plc (NASDAQ:VRNA) StockVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 208,696 shares of the stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $9.33, for a total value of $1,947,133.68. Following the transaction, the chief executive officer now directly owns 13,590,168 shares in the company, valued at approximately $126,796,267.44. The trade was a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.May 31, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up - Time to Buy?Verona Pharma (NASDAQ:VRNA) Shares Gap Up - Here's What HappenedMay 31, 2025 | marketbeat.com10,310 Shares in Verona Pharma plc (NASDAQ:VRNA) Bought by NorthCrest Asset Manangement LLCNorthCrest Asset Manangement LLC acquired a new position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,310 shares of the company's stock, valMay 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $309,076.96 in StockMay 30, 2025 | insidertrades.comJim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”May 29, 2025 | insidermonkey.comVerona Pharma (NASDAQ:VRNA) Sets New 52-Week High - Still a Buy?Verona Pharma (NASDAQ:VRNA) Hits New 1-Year High - What's Next?May 28, 2025 | marketbeat.comTwo Sigma Investments LP Grows Position in Verona Pharma plc (NASDAQ:VRNA)Two Sigma Investments LP raised its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 117.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 152,104 shares of the company's stock aMay 27, 2025 | marketbeat.comAmeriprise Financial Inc. Makes New Investment in Verona Pharma plc (NASDAQ:VRNA)Ameriprise Financial Inc. acquired a new position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 117,100 shares of the company's stock, valued at approximately $5,438,000. Ameriprise Financial Inc. oMay 26, 2025 | marketbeat.comCetera Investment Advisers Has $1.08 Million Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)Cetera Investment Advisers raised its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 113.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,265 shares of the company's stock after purchasing an additiMay 25, 2025 | marketbeat.comBNP Paribas Financial Markets Trims Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)BNP Paribas Financial Markets lessened its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 73.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,740 shares of the comMay 25, 2025 | marketbeat.comCastleark Management LLC Makes New $8.63 Million Investment in Verona Pharma plc (NASDAQ:VRNA)Castleark Management LLC purchased a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 185,860 shares of the company's stock, valued at approximately $8,631,000. Castleark Management LMay 23, 2025 | marketbeat.comWoodline Partners LP Grows Position in Verona Pharma plc (NASDAQ:VRNA)Woodline Partners LP grew its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 1.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 516,605 shares of the company's stock after buying an additionaMay 23, 2025 | marketbeat.comVelan Capital Investment Management LP Acquires New Stake in Verona Pharma plc (NASDAQ:VRNA)Velan Capital Investment Management LP bought a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company's stock, valued at approximatMay 21, 2025 | marketbeat.comVestal Point Capital LP Purchases Shares of 495,000 Verona Pharma plc (NASDAQ:VRNA)Vestal Point Capital LP purchased a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 495,000 shares of the company's stock, valued at approximately $22,May 21, 2025 | marketbeat.comVerona Pharma Announces June 2025 Investor Conference ParticipationMay 21, 2025 | globenewswire.comVerona Pharma plc (NASDAQ:VRNA) Shares Bought by Lazard Asset Management LLCLazard Asset Management LLC grew its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 36.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 34,503 shares of the company's stock after purchasing an additional 9,267 shares durMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys New Position in Verona Pharma plc (NASDAQ:VRNA)Point72 Asset Management L.P. bought a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 711,007 shares of the company'sMay 19, 2025 | marketbeat.com1,821,019 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by RTW Investments LPRTW Investments LP purchased a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,821,019 shares of the company's stock, valued at approximately $84,568,000. VMay 18, 2025 | marketbeat.com39,369 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by Point72 Europe London LLPPoint72 Europe London LLP bought a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 39,369 shares of the company's stock, valued at approximately $1,828,000.May 18, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Stake Lifted by Parkman Healthcare Partners LLCParkman Healthcare Partners LLC lifted its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 15.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 720,657 shares of the company's stock after acquiring an additionalMay 16, 2025 | marketbeat.comNicholas Investment Partners LP Invests $7.19 Million in Verona Pharma plc (NASDAQ:VRNA)Nicholas Investment Partners LP purchased a new position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 154,814 shares of the company's stock,May 16, 2025 | marketbeat.comOctagon Capital Advisors LP Sells 1,263,936 Shares of Verona Pharma plc (NASDAQ:VRNA)Octagon Capital Advisors LP lessened its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 68.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 571,264 shares of the company's stock after selling 1,263,936 shares during the quarter. VeroMay 15, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Bought by Janus Henderson Group PLCJanus Henderson Group PLC grew its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 59.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,667,165 shares of the company's stock after puMay 15, 2025 | marketbeat.comRaymond James Financial Inc. Invests $225,000 in Verona Pharma plc (NASDAQ:VRNA)Raymond James Financial Inc. purchased a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,855 shares of the company's stock, valued at approximately $225,000. Several other hedge funds anMay 15, 2025 | marketbeat.comFred Alger Management LLC Takes $1.34 Million Position in Verona Pharma plc (NASDAQ:VRNA)Fred Alger Management LLC acquired a new position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 28,945 shares of the company's stock, valuedMay 13, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Acquired by Barclays PLCBarclays PLC lifted its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 1,379.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,313 shares of the company's stock after buying an additional 4,954 sMay 13, 2025 | marketbeat.comFindell Capital Management LLC Makes New $8.36 Million Investment in Verona Pharma plc (NASDAQ:VRNA)Findell Capital Management LLC purchased a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 180,000 shares of the company's stock, valued at approximMay 11, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Has $5.89 Million Stock Position in Verona Pharma plc (NASDAQ:VRNA)The Manufacturers Life Insurance Company grew its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 20.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 126,730 shares of the company's stock after aMay 10, 2025 | marketbeat.comDeep Track Capital LP Sells 2,330,025 Shares of Verona Pharma plc (NASDAQ:VRNA)Deep Track Capital LP reduced its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 73.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 850,000 shares of the company's stockMay 9, 2025 | marketbeat.comDuquesne Family Office LLC Purchases 201,535 Shares of Verona Pharma plc (NASDAQ:VRNA)Duquesne Family Office LLC boosted its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 29.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 887,580 shares of the company's stock after purchasing an additional 20May 9, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Insider Sells $1,014,158.88 in StockMay 9, 2025 | insidertrades.com Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Media Mentions By Week VRNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRNA News Sentiment▼1.261.01▲Average Medical News Sentiment VRNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRNA Articles This Week▼57▲VRNA Articles Average Week Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News TEVA News SMMT News GMAB News ITCI News RDY News MRNA News ASND News VTRS News QGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRNA) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRNA Stock Free VRNA Stock Alerts